Recent Insights into Immuno-Oncology

The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated through CAR-T, leading to the inhibition of CAR-T cell activity via the PD-1 pathway.

At the 2024 Recent Insights into Immuno-Oncology Conference, WuXi AppTec presented a poster describing an engineered CAR-T therapy that targets mesothelin and concurrently expresses a membrane-bound PD-1 receptor. The authors demonstrate that inclusion of a PD-1 immune checkpoint blockade protein can overcome PD-L1 mediated CAR-T inhibition, resulting in enhanced and prolonged CAR-T cell tumor suppression.

Poster_Recent Insights IO_Armoring CAR-T Therapy with PD-1 Blockade

Download